The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just an enlightened here.
What is the advantage of phase 2a over phase1b?
There is a degree of similarity in the to a certain extent both these trials achieve the same thing.
Effectively proof of concept that the inhibitor is or will likely provide a viable therapeutic treatment for Psoroasis.
Phase 1 trial establishes safety profile.
Phase 1b small number of patients up to several 10's
Can be no increase in therapeutic treatment, basically no exceeding 300mg per day. I doubt we would need anywhere near 30 mg per day anyhow for Psoriasis.
Phase 2a similar number of patients as to Phase 1b. Proof of concept.
Phase 2b, a larger number of patients normally around a couple if hundred. Increased dosaging v effectiveness here. The purpose of this Phase is to establish statistical data ( accuracy is related to the magnitude of count) that will indicate to a certain degree not only the tolerability, safety, but also efficacy.
When all proceeds fine then progression to phase 3 typically involving 1 to 2 thousand people.
At this stage, we are looking at long term effects and the evaluation of the compound continues dnd if this particular compound exceeds the safety and efficacy of the current standard of care, then apply for clinical approval.
Phase 2 by the very nature will have far more clout and add value as you have gone from phase 1 to phase 2.
Phase1b cab be put into progress znd whilst progressing plans can be made, via whatever means onlicence, partnership, or buyout can be decided on.
Regards
Apologies if a few mistakes as mobile phone misbehaving. It not allow me to read through.
What a charmer this Nik nak is...
You're spot on, Officemanager đź‘Ť
I too missed the indication of going straight on to phase 2a. The reason I missed it was that I took it to be a (hope-filled) aspiration, i.e. that 1b could be done over the second half of 2024 and 2a, subject - mind you - to funding etc., begun by year-end. Chairman's statements are the place to bang the drum. But was I wrong?
Thanks for the link HBD good to read over the Edison report again, it comes across if data & safety are good then it's a wait and see if we can get a partner license deal otherwise it's more dilution, also moot point on P2a over 1b Edison does not differentiate and it's just down to wait and see. Feels like we are in a sidewards holding position when before we would have finished P1b this year....
I’m not even going to entertain you’re crap office I’ve got my answers from two other nice posters you can stew in you’re own arrogance.
NikNak222, I've filtered every name you come up with and will this one too, I won't be alone.
I hope you are right HBD. But, after the rollercoaster ride Sareum has had I’m being cautious with any nearer term share price predictions.
Have a good evening.
Bill
Officemanager it’s just twisted and bitter people like you that don’t allow genuine people to ask questions. I feel sorry for anyone that has to tolerate your arrogance in real life. At least there are some nice people out there that have answered the questions I had.
Evening Billy - although 75p would get the m/cap back to pre-RF levels, it doesn't take into account the progress made since then i.e. completion of SAD & food effect stages without adverse effects and the intention to jump forward to P2a rather than P1b. Each of those steps should add to that notional 75p per share so maybe ÂŁ1 is nearer the mark.
Hmmmmmm, just don't start with the not so subtle de-ramping, that's why you often get slapped down.
Smart yes relatively new to this company hence the question and thank you for your answers rather than biting my head off as sometimes a lot of investors on forums do. Appreciated.
I also have 75p in mind. It’s where the price was before Riverfort came along, accounting for the 50% or so dilution since then.
If you are new, then this question is fine. However one should argue why it so much in the first place. If it was not for the death spiral finance by RF, we would have never seen such a pathetically low SP value. So the answer to your question is that with RF chapter almost closed, the share is moving back to its original value which in my view is anywhere between 60p to 75p.
Because the deal with Riverfort worked out badly and had the share price in a death spiral. Additionally Riverfort stopped the flow of funds to Sareum and they were at risk of going under. That is thankfully now behind Sareum, hence the share price lifting.
If they need a raise or potential partnership (hopefully) why the hell did this shoot up so much with the recent news regarding the RF?
They might not need to fundraise as the Edison Report (see below) notes, "we expect the company is likely to seek non-dilutive funding in the form of a partnership".
https://www.edisoninvestmentresearch.com/?ACT=18&ID=33426
Correction. Should have read: Yes, that is correct. They need the funds to plan for and then execute the P2a trial and fund business operating expenses in the meantime. I’m expecting a raise in the Autumn.
Yes, that is correct. They need the funds to plan for and then execute the P1a trial and fund business operating expenses in the meantime. I’m expecting a raise in the Autumn.
Reading the half year report again, are they in effect saying they need to fundraise again post top line results of the MAD?
Lesson learnt- read the chairman’s comments ! Grossly under valued , even more than I thought and we all know ( sub results) .
Hi Basil - and just to add, recent RNS make reference to the SAD/MAD/food element of the trial and also P2a. No mention at all of P1b. Coupled with what they've told us regarding being able to reach concentrations in the blood where it could be therapeutic, we have a pretty nailed-on certainty that good news is on the horizon.
There are a lot of shares in the very sticky hands of some LTH's. I know I gave myself a self imposed limit of 100,000 shares but if price remains low I won't be able to help myself. Wife has given me green light to move to 200,000 if share price drops or doesn't breach 60p.
Roll on next week.
Elcap
For the avoidance of doubt: “we endeavour to be in a position to commence a Phase 2a study in psoriasis patients before the end of 2024.” - Sareum
Thank you . Much appreciated.
See Chairman's statement, half yearly report.
The multiple ascending dose (MAD) portion of SDC-1801 is nearing completion. Sareum aims to conclude this part of the trial by the end of Q2 2024. Subject to data review, additional funding and/or potential licencing opportunities, we endeavour to be in a position to commence a Phase 2a study in psoriasis patients before the end of 2024.